Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Cortexin

Cerebral Cortex Polypeptide Complex

Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.

Cortexin is a Russian polypeptide preparation from cattle cerebral cortex, prescribed for decades across Russia and the CIS for stroke, TBI, and cognitive decline, but that clinical use has not been confirmed by rigorous Western trials. The only English-language systematic review (Bakr et al., 2021) located a single Cortexin RCT (80 participants), could not meta-analyze it, and graded the whole animal-derived-nootropic literature as low-to-very-low certainty with moderate-to-high risk of bias; small recent Russian studies such as the 2025 MoCA report (n=30, open observation) are preliminary, so the evidence sits at the traditional/anecdotal level.

FDA
Not approved (US); registered prescription drug in Russia and several CIS states
WADA
Not listed on the WADA Prohibited List

Reference only. Not medical advice.

What can go wrong

Bovine cerebral-cortex origin carries a theoretical BSE/prion (TSE) concern; complex undefined mixture; no modern Western toxicology or GMP oversight; all efficacy data from Russia and Eastern Europe.

Talk to a clinician before taking this. The Atlas can tell you what has been studied about Cortexin. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.

A complex of polypeptides from bovine cerebral cortex, approved in Russia for stroke, TBI, and cognitive decline. Genuine positive Russian/Eastern European data.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Post-stroke recovery
  • TBI rehabilitation
  • Cognitive decline

How it is supposed to work

Cortexin is a complex of polypeptides extracted from animal cerebral cortex, used in Russia as a neuroprotective preparation for stroke, brain injury and cognitive disorders. As a tissue extract of many components, its active basis is not a single defined molecule, which limits mechanistic clarity even though it is one of the most clinically used items in the tradition.

Cortexin is a polypeptide complex from animal cerebral cortex, not a single defined molecule, which makes it a close conceptual cousin of Cerebrolysin, the porcine brain-peptide preparation. It is distinct from the ultra-short synthetic bioregulators like Pinealon and Cortagen, though it shares their Russian neuropeptide tradition.

Type
Brain polypeptide complex
Source
Animal cerebral cortex
Use
Neurology, by injection
Region
Russia and CIS
Evidence
Regional clinical
Western RCT
Limited

A Russian Brain-Extract Drug, Familiar If You Know Cerebrolysin

Cortexin is best understood by analogy to Cerebrolysin, which is covered elsewhere in this library: both are brain-tissue-derived peptide mixtures, widely prescribed across Russia and the post-Soviet world for stroke and cognitive decline, and both face the same Western skepticism. The mechanism is described as broadly neurotrophic and neuroprotective, but because the product is a complex mixture rather than a defined molecule, the precise active components are unclear. The evidence is mostly Russian clinical use and regional trials, with little rigorous independent Western validation, and analyses of this category of brain-extract drugs have generally found the high-quality evidence thin. It is a genuinely established regional medicine whose effectiveness the broader evidence base has not confirmed.

Safety in detail

Cortexin is prepared from cattle central-nervous-system tissue, which regulators classify among the highest-risk materials for transmissible spongiform encephalopathy, so bovine CNS extracts are restricted in US and EU human products; no confirmed prion transmission from Cortexin has been reported, and no modern independent safety, toxicology, or purity assessment is publicly available.

  • Reported safety in decades of Russian clinical use is described as clean, with few serious adverse events, but that record comes largely from within the same research tradition that developed the peptides and has not been independently verified in Western trials.
  • Long-term safety in rigorous, controlled human studies is essentially uncharacterized outside that tradition.
  • Most material sold internationally is gray-market or supplement-grade, so unverified identity, dose and purity are the dominant practical risks.
  • Not FDA-approved for any use; claims of disease treatment are not supported by Western regulatory review.

Children and teenagers

Cortexin is used in pediatric neurology within Russia for specific conditions, but it is unapproved elsewhere and should never be used in children outside qualified medical supervision. There is no appropriate self-directed pediatric use.

What people get wrong

Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Cortexin is a marketed pharmaceutical across Russia and the CIS, where it is a familiar prescription product, and it reaches Western users mainly through import and gray-market channels. Its economy is regional medicine rather than the global longevity market.

How we got here

Cortexin is a Russian polypeptide brain-extract nootropic manufactured by Geropharm, made from low-molecular-weight water-soluble polypeptide fractions of cattle and pig cerebral cortex. It is widely prescribed across Russia and CIS countries for stroke, traumatic brain injury, and cognitive impairment, but is not approved in the US or EU. It should be distinguished from the synthetic short-peptide Cortagen and related Cortexin-family cytamin/cortexin peptides, which are chemically defined rather than whole tissue extracts.

Cortexin belongs to the Soviet and Russian tradition of tissue-derived neuropeptide drugs, alongside Cerebrolysin, and became a standard regional treatment for neurological conditions long before the synthetic short-peptide bioregulators were developed.

The numbers behind the grade

Type
Cortical peptide extract
Target
Brain / cortex
Russia
Registered, widely used
FDA
Not approved
Evidence
Russian clinical
Western RCTs
Scarce

The people taking it

One of the most clinically used neuro-preparations in the Russian tradition, widely prescribed there for brain conditions.

Cortexin’s users are patients and clinicians in Russia and neighboring countries, where it is mainstream neurology, plus nootropic and recovery enthusiasts abroad who import it.

Used extensively in Russia for stroke, brain injury and cognitive disorders, and internationally as a neuro bioregulator. Its standing rests on Russian clinical practice rather than Western trials.

Set against the alternatives

Cortexin’s closest relative is Cerebrolysin, another animal-brain peptide mixture used the same way in the same regions and met with the same Western caution. Against the defined synthetic brain bioregulators like Pinealon and Cortagen, Cortexin is the older, undefined-mixture approach rather than a single-sequence peptide. And against a Russian synthetic neuropeptide like Semax, it is the broad extract rather than the targeted molecule. The common thread is a body of regional clinical confidence that has not crossed into the Western evidence base.

What we do not know

  • Whether independent, Western randomized trials confirm any of the claimed clinical effects.
  • Whether the proposed DNA-binding, gene-regulating mechanism actually operates in human tissue at the doses used.
  • Why, after forty years and hundreds of papers, replication outside the originating institute remains so limited.
  • Whether results from complex tissue extracts (Cytomaxes) translate to the defined synthetic peptides (Cytogens) sold alongside them.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

Available internationally as oral or injectable bioregulator supplements (Cytogen and Cytomax lines) and as research-use-only peptide vials, with legal status varying by country. None is an FDA-approved medicine, so there is no regulated US prescription route; the honest course is to treat the claims with caution and consult a clinician.

Material reaches international buyers two ways: as branded Cytogen (synthetic) or Cytomax (animal-tissue extract) supplements produced in Russia, and as research-use-only vials, much of it synthesized in China. Neither route guarantees the identity or potency the label claims, so an independent certificate of analysis is the only real check and is uncommon.

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Cortexin.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Supply chain. We have not mapped where it is made.
  • What could change. No forward-looking summary yet.

Sources

The studies that matter

  • Russian clinical use1990s-2020s

    Cortexin is among the most extensively used and studied bioregulator preparations in Russian neurology, for stroke, traumatic brain injury and cognitive impairment.

  • Independent replicationlimited

    Despite heavy use in Russia, independent Western randomized trials are scarce.